Product Description
Mechanisms of Action: Cell Wall Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Intramuscular,Oral,Vaginal
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Bangladesh | Brazil | Canada | Chile | China | Colombia | Egypt | Estonia | France | Germany | Greece | Ireland | Italy | Jordan | Korea | Lebanon | New Zealand | Pakistan | Peru | Philippines | Portugal | Russia | Saudi Arabia | Slovenia | South Africa | Spain | Taiwan | Thailand | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: CHU DE POITIERS
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2022-003262-20 | P3 |
Active, not recruiting |
Unknown |
2026-01-19 |